Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Janus Kinase Inhibitors and Risk of Venous Thromboembolism: A Systematic Review and Meta-analysis
Jawad Bilal, Irbaz Bin Riaz, Syed Arsalan Ahmed Naqvi, et al.
Mayo Clinic Proceedings (2021) Vol. 96, Iss. 7, pp. 1861-1873
Closed Access | Times Cited: 18

Showing 18 citing articles:

Safety of baricitinib for the treatment of rheumatoid arthritis over a median of 4.6 and up to 9.3 years of treatment: final results from long-term extension study and integrated database
Peter C. Taylor, Tsutomu Takeuchi, Gerd R Burmester, et al.
Annals of the Rheumatic Diseases (2021) Vol. 81, Iss. 3, pp. 335-343
Open Access | Times Cited: 116
Evaluation of VTE, MACE, and Serious Infections Among Patients with RA Treated with Baricitinib Compared to TNFi: A Multi-Database Study of Patients in Routine Care Using Disease Registries and Claims Databases
Claudia A. Salinas, Anthony Louder, Jennifer M. Polinski, et al.
Rheumatology and Therapy (2022)
Open Access | Times Cited: 81
Association of Risk of Incident Venous Thromboembolism With Atopic Dermatitis and Treatment With Janus Kinase Inhibitors
Tai‐Li Chen, Ling-Ling Lee, Huei‐Kai Huang, et al.
JAMA Dermatology (2022) Vol. 158, Iss. 11, pp. 1254-1254
Open Access | Times Cited: 45
Safety of Upadacitinib in Immune-Mediated Inflammatory Diseases: Systematic Literature Review of Indirect and Direct Treatment Comparisons of Randomized Controlled Trials
Eduardo Mysler, Gerd R Burmester, Christopher D. Saffore, et al.
Advances in Therapy (2024) Vol. 41, Iss. 2, pp. 567-597
Open Access | Times Cited: 9
A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?
Christine Liu, Jacqueline Kieltyka, Roy Fleischmann, et al.
Arthritis & Rheumatology (2021) Vol. 73, Iss. 12, pp. 2166-2178
Open Access | Times Cited: 52
Risk of venous thromboembolism with janus kinase inhibitors in inflammatory immune diseases: a systematic review and meta-analysis
J Zhang, Wenhui Li, Mingli Gong, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 17
Risk of venous thromboembolism associated with Janus kinase inhibitors for rheumatoid arthritis: case presentation and literature review
Shunsuke Mori, Fumihiko Ogata, Ryusuke Tsunoda
Clinical Rheumatology (2021) Vol. 40, Iss. 11, pp. 4457-4471
Open Access | Times Cited: 35
Upadacitinib for Patients with Rheumatoid Arthritis: A Comprehensive Review
Raimón Sanmartí, Héctor Corominas
Journal of Clinical Medicine (2023) Vol. 12, Iss. 5, pp. 1734-1734
Open Access | Times Cited: 15
Cardiovascular safety of Janus kinase inhibitors in patients with rheumatoid arthritis: systematic review and network meta-analysis
Qiang‐hua Wei, Hui Wang, Jianglin Zhao, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 15
Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies
Madison Alexander, Yiming Luo, Giorgio Raimondi, et al.
Pharmaceuticals (2021) Vol. 15, Iss. 1, pp. 48-48
Open Access | Times Cited: 29
Risk of Venous Thromboembolism Among Adults With Atopic Dermatitis
Tai‐Li Chen, Wan‐Ting Huang, Ching‐Hui Loh, et al.
JAMA Dermatology (2023) Vol. 159, Iss. 7, pp. 720-720
Open Access | Times Cited: 11
Venous Thromboembolism in Rheumatoid Arthritis: The Added Effect of Disease Activity to Traditional Risk Factors
Mohammed A. Omair, Sara A Alkhelb, Sadeen E Ezzat, et al.
Open Access Rheumatology Research and Reviews (2022) Vol. Volume 14, pp. 231-242
Open Access | Times Cited: 12
The Emerging Safety Profile of JAK Inhibitors in Rheumatic Diseases
Jasvinder A. Singh
BioDrugs (2023) Vol. 37, Iss. 5, pp. 625-635
Closed Access | Times Cited: 7
Pharmacologic Anticoagulation Is Associated With a Lower Risk of Recurrent Venous Thromboembolic Events During Janus Kinase Inhibitor Use for Patients With a Prior Thrombosis
Jeffrey A. Lowell, G.V.R.K. Sharma, Arun Swaminath, et al.
Inflammatory Bowel Diseases (2024)
Closed Access | Times Cited: 2
Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19
Mar Masiá, Sergio Padilla, José Alberto García, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 15
Treatment options for moderate to severe atopic dermatitis
Dana Wallace
Allergy and Asthma Proceedings (2022) Vol. 43, Iss. 6, pp. 474-493
Closed Access | Times Cited: 9
JAK inhibitor treatment for inflammatory diseases: excess or no excess risk of venous thromboembolism
Yachar Dawudi, Samuel Benarroch, H. L. Helfer, et al.
Research and Practice in Thrombosis and Haemostasis (2024) Vol. 9, Iss. 1, pp. 102667-102667
Open Access | Times Cited: 1
Oral Janus kinase inhibitors and venous thromboembolic events in atopic dermatitis: protocols for a case–time control study and a nested case-control study based on the French national health insurance (SNDS) cohort
Pauline Berthe, Lucie‐Marie Scailteux, Alain Lescoat, et al.
BMJ Open (2022) Vol. 12, Iss. 9, pp. e059979-e059979
Open Access | Times Cited: 6
Page 1

Scroll to top